TARA trades 421.7% below Wall Street's consensus target of $12.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TARA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Protara Therapeutics, Inc. (TARA) has a Wall Street consensus price target of $12.00, based on estimates from 6 covering analysts. With the stock currently trading at $2.30, this represents a potential upside of +421.7%. The company has a market capitalization of $129M.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TARA trades at a trailing P/E of -1.8x. Analysts expect EPS to grow -20.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RCKTRocket Pharmaceuticals, Inc. | $260M | $2.38 | $5.32 | +123.1% | Buy | — | 19 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $15.43 | $25.54 | +65.5% | Buy | — | 34 |
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.23 | $30.05 | +41.5% | Buy | 34.1x | 37 |
 PRTAProthena Corporation plc | $417M | $7.97 | $30.00 | +276.4% | Buy | 67.2x | 28 |
 URGNUroGen Pharma Ltd. | $1.2B | $24.75 | $58.60 | +136.8% | Buy | — | 16 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.2B | $25.55 | $41.80 | +63.6% | Buy | 61.9x | 12 |
 NKTRNektar Therapeutics | $1.2B | $37.26 | $121.33 | +225.6% | Buy | — | 33 |
 CLDXCelldex Therapeutics, Inc. | $2.0B | $29.87 | $66.80 | +123.6% | Buy | — | 20 |
Quick answers to the most common questions about buying TARA stock.
The consensus Wall Street price target for TARA is $12, representing 421.7% upside from the current price of $2.3. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TARA has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 421.7% upside from current levels.
TARA's current price is $2.3 with a consensus target of $12 (421.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $12 for TARA, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
TARA is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TARA stock forecast based on 6 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TARA, with a "Buy" consensus rating and $12 price target (421.7% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TARA analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.